Want to see LYRA full AI Analyst Report?
LYRA Stock Chart & Stats
$1.98
>-$0.01(-3.42%)
At close: 4:00 PM EST
$1.98
>-$0.01(-3.42%)
Day’s Range― - ―
52-Week Range$0.31 - $8.98
Previous CloseN/A
Volume832.93K
Average Volume (3M)9.85K
Market Cap
$957.37K
Enterprise Value$15.15M
Total Cash (Recent Filing)$15.89M
Total Debt (Recent Filing)$30.26M
Price to Earnings (P/E)―
Beta3.56
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-18.62
Shares Outstanding1,774,882
10 Day Avg. Volume6,177
30 Day Avg. Volume9,854
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.46
Price to Sales (P/S)120.22
P/FCF Ratio-1.65
Enterprise Value/Market Cap15.82
Enterprise Value/Revenue38.06
Enterprise Value/Gross Profit38.06
Enterprise Value/Ebitda-0.55
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.02
Revenue Forecast (FY)$700.00K
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsPositive outcomes from ENLIGHTEN 2 and a larger treatment effect in patients with higher ethmoidal disease burden support confidence in the therapy's effectiveness.
Regulatory PathwayFDA feedback that outlines a clear path to a New Drug Application for chronic rhinosinusitis patients without nasal polyps strengthens the regulatory prospects for approval.
Trial Design EnhancementsEnhanced Phase 3 study features such as independent review panels and an open-label extension are designed to improve statistical power and accuracy of the results.
Bears Say
Delayed Data AvailabilityA long interval before topline study results creates an extended period of uncertainty that delays potential value realization for investors.
Financing RiskThe need to raise cash to fund the study creates financing risk that could lead to shareholder dilution or increased debt.
Patient Selection And EnrollmentProtocol adjustments to remove background saline irrigation and tighten CT opacification criteria may complicate differentiation among similar patients and slow enrollment.
Lyra Therapeutics News
LYRA FAQ
What was Lyra Therapeutics, Inc.’s price range in the past 12 months?
Lyra Therapeutics, Inc. lowest stock price was $0.31 and its highest was $8.98 in the past 12 months.
What is Lyra Therapeutics, Inc.’s market cap?
Lyra Therapeutics, Inc.’s market cap is $957.37K.
When is Lyra Therapeutics, Inc.’s upcoming earnings report date?
Lyra Therapeutics, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 30 days.
How were Lyra Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Lyra Therapeutics, Inc. overvalued?
According to Wall Street analysts Lyra Therapeutics, Inc.’s price is currently Overvalued.
Does Lyra Therapeutics, Inc. pay dividends?
Lyra Therapeutics, Inc. does not currently pay dividends.
What is Lyra Therapeutics, Inc.’s EPS estimate?
Lyra Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lyra Therapeutics, Inc. have?
Lyra Therapeutics, Inc. has 1,774,882 shares outstanding.
What happened to Lyra Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lyra Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LYRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.
Technical Analysis
XTL Biopharmaceuticals Sponsored ADR
―
Mustang Bio
―
Bolt Biotherapeutics
―
TransCode Therapeutics
―
Silexion Therapeutics
―
Ownership Overview
91.65% Insiders
0.85% Mutual Funds
5.86% Other Institutional Investors
1.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---